Larimar Therapeutics Inc
NASDAQ:LRMR
Relative Value
There is not enough data to reliably calculate the relative value of LRMR.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
LRMR Competitors Multiples
Larimar Therapeutics Inc Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
US |
Larimar Therapeutics Inc
NASDAQ:LRMR
|
439.6m USD | 0 | -12.7 | -8.5 | -8.4 | ||
US |
Abbvie Inc
NYSE:ABBV
|
288.7B USD | 5.3 | 59.9 | 13 | 19.8 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
147.9B USD | 5.2 | 22 | 16.4 | 24.5 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103B USD | 10.4 | 28.5 | 22.8 | 23.8 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
98.5B USD | 7.5 | 24.9 | 16.5 | 18.2 | ||
AU |
CSL Ltd
ASX:CSL
|
132.6B AUD | 6.1 | 35 | 21.2 | 26.3 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 14.4 | 7.9 | 10.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
41.7B USD | 6.1 | -8.8 | -9.3 | -7.9 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.3B USD | 3.2 | 27 | 14.6 | 18.1 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |